The role of urine and serum biomarkers in the early detection of ovarian epithelial tumours

References

• Anaya, J. 2016. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Computer Science, 2, e67.
   Google Scholar
• Badgwell, D. and Bast, R. C., Jr, 2007. Early detection of ovarian cancer. Disease Markers, 23 (5–6), 397–410.
   PubMed Web of Science ®Google Scholar
• Badgwell, D., et al., 2007. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecologic Oncology, 106 (3), 490–497.
   PubMed Web of Science ®Google Scholar
• Baron, A. T., et al., 2003. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiology and Biomarkers Prevention, 12 (2), 103–113.
   PubMed Web of Science ®Google Scholar
• Bast, R. C., Hennessy, B. and Mills, G. B., 2009. The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer, 9 (6), 415–428.
   PubMed Web of Science ®Google Scholar
• Bellone, S., et al., 2009. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. International Journal of Gynecologic Cancer, 19 (5), 19.
   Web of Science ®Google Scholar
• Bettegowda, C., et al., 2014. Detection of circulating tumor DNA in early-and late-stage human malignancies. Science Translational Medicine, 6 (224), 224ra24–224ra24.
   PubMed Web of Science ®Google Scholar
• Birrer, M. J., et al., 2015. Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP)±bevacizumab (BEV) for epithelial ovarian cancer (EOC).
   Google Scholar
• Blyuss, O., et al., 2015. Serial patterns of ovarian cancer biomarkers in a prediagnosis longitudinal dataset. BioMed Research International, 2015, 1–6.
   Web of Science ®Google Scholar
• Brodsky, B. S., et al., 2017. The economic impact of increased utilization of multivariate assay testing to guide the treatment of ovarian cancer: implications for payers. American Health & Drug Benefits, 10 (7), 351–359.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature, 474 (7353), 609.
   PubMed Web of Science ®Google Scholar
• Cesano, A. and Warren, S., 2018. Bringing the next generation of immuno-oncology biomarkers to the clinic. Biomedicines, 6 (1), 14.
   PubMed Web of Science ®Google Scholar
• Chen, F., et al., 2018. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Management and Research, 10, 1313–1318.
   PubMed Web of Science ®Google Scholar
• Chovatiya, R. and Medzhitov, R., 2014. Stress, inflammation, and defense of homeostasis. Molecular Cell, 54 (2), 281–288.
   PubMed Web of Science ®Google Scholar
• Ciriello, G., et al., 2013. The emerging landscape of oncogenic signatures across human cancers. Nature Genetics, 45 (10), 1127–1133.
   PubMed Web of Science ®Google Scholar
• Clarke, C. H., et al., 2011. Proteomic biomarkers apolipoprotein A1 truncated transthyretin and connective tissue activating protein III enhances the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecologic Oncology, 122 (3), 548–553.
   PubMed Web of Science ®Google Scholar
• Coleman, R. L., et al., 2016. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. American Journal of Obstetrics and Gynecology, 215 (1), 82.e1–e1.
   PubMed Web of Science ®Google Scholar
• Cooper, B. C., et al., 2002. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clinical Cancer, 8 (10), 3193–3197.
   Google Scholar
• Coticchia, C. M., Yang, J. and Moses, M. A., 2008. Ovarian cancer biomarkers: current options and future promise. Journal of the National Comprehensive Cancer Network , 6 (8), 795–802.
   PubMedGoogle Scholar
• Cramer, D. W., et al., 2011. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prevention Research (Philadelphia, PA), 4 (3), 365–374.
   PubMed Web of Science ®Google Scholar
• Decramer, S., et al., 2008. Urine in clinical proteomics. Molecular & Cellular Proteomics, 7 (10), 1850–1862.
   PubMed Web of Science ®Google Scholar
• Diamandis, E. P., et al., 2003. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. Journal of Clinical Oncology, 21 (6), 1035–1043.
   PubMed Web of Science ®Google Scholar
• Duffy, M. J., et al., 2005. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. International Journal of Gynecologic Cancer, 15 (5), 679–691.
   PubMed Web of Science ®Google Scholar
• Gorelik, E., et al., 2005. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention, 14 (4), 981–987.
   PubMed Web of Science ®Google Scholar
• Günel, T., et al., 2018. Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer. Archives of Gynecology and Obstetrics, 298 (6), 1173–1180.
   PubMed Web of Science ®Google Scholar
• Guo, J., et al., 2017. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: a meta-analysis. Open Medicine (Warsaw, Poland), 12 (1), 131–137.
   PubMedGoogle Scholar
• Halvaei, S., et al., 2018. Exosomes in cancer liquid biopsy: a focus on breast cancer. Molecular Therapy Nucleic Acids, 10, 131–141.
   PubMedGoogle Scholar
• Han, C., et al., 2018. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology, 149 (3), 585–591.
   PubMed Web of Science ®Google Scholar
• Hellstrom, I., et al., 2010. Detection of the HE4 protein in the urine as a biomarker for ovarian neoplasms. Cancer Letters, 296 (1), 43–48.
   PubMed Web of Science ®Google Scholar
• Herzog, T. J., et al., 2011. Correlation between CA-125 serum level and response by RECIST in phase III recurrent ovarian cancer study. Gynecologic Oncology, 122 (2), 350–355.
   PubMed Web of Science ®Google Scholar
• Holschneider, C. H. and Berek, J. S., 2000. Ovarian cancer: epidemiology, biology, and prognostic factors. Seminars Seminars in Surgical Oncology, 19 (1), 3–10.
   PubMed Web of Science ®Google Scholar
• Hu, X., et al., 2009. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecologic Oncology, 114 (3), 457–464.
   PubMed Web of Science ®Google Scholar
• Jacobs, I. J. and Menon, U., 2004. Progress and challenges in screening for early detection of ovarian cancer. Molecular & Cellular Proteomics, 3 (4), 355–366.
   PubMed Web of Science ®Google Scholar
• Jia, Y., et al., 2017a. Exosome: an emerging biomarker in breast cancer. Oncotarget, 8 (25), 41717–41733.
   PubMed Web of Science ®Google Scholar
• Jia, M. M., et al., 2017b. Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis. Oncotarget, 8 (6), 9660–9671.
   PubMedGoogle Scholar
• Jing, J. and Gao, Y., 2018. Urine biomarkers in the early stages of diseases: current status and perspective. Discovery Medicine, 25 (136), 57–65.
   PubMed Web of Science ®Google Scholar
• Kappelmayer, J. Antal-Szalmás, Y.P., and Nagy Jr, B., 2015. Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders. Clinica Chimica Acta, 438, 35–42.
   PubMed Web of Science ®Google Scholar
• Kim, Y. W., et al., 2012. Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PLoS One, 7, e44960.
   PubMed Web of Science ®Google Scholar
• Kim, K., et al., 2009. Development and validation of a protein-based signature for the detection of ovarian cancer. Clinics in Laboratory Medicine, 29 (1), 47–55.
   PubMed Web of Science ®Google Scholar
• Kolch, W., et al., 2005. Capillary electrophoresis–mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrometry Reviews, 24 (6), 959–977.
   PubMed Web of Science ®Google Scholar
• Laganà, A. L., et al., 2015. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. European Journal of Gynaecological Oncology, 36 (5), 495–505.
   PubMed Web of Science ®Google Scholar
• Ławicki, S., et al., 2013. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and subtypes of epithelial ovarian tumors. Journal of Ovarian Research, 6 (1), 45–11.
   PubMed Web of Science ®Google Scholar
• Li, J., et al., 2009. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Review of Molecular Diagnostics, 9 (6), 555–566.
   PubMed Web of Science ®Google Scholar
• Liao, J. B., et al., 2015. Detection of the HE4 protein in the urine as a biomarker for ovarian neoplasms: clinical correlates. Gynecologic Oncology, 137 (3), 430–435.
   PubMed Web of Science ®Google Scholar
• Lincoln, S. E., et al., 2020. Yield and utility of germline testing following tumor sequencing in patients with cancer. JAMA Network Open, 3 (10), e2019452–e2019452.
   PubMed Web of Science ®Google Scholar
• Lokshin, A. E., et al., 2006a. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecologic Oncology, 102 (2), 244–251.
   PubMed Web of Science ®Google Scholar
• Lokshin, A. E., et al., 2006b. Multimarker assay for early diagnosis of ovarian cancer. Cancer Research, 66, 155.
   Google Scholar
• Lowe, K. A., et al., 2008. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention, 17 (9), 2480–2487.
   PubMed Web of Science ®Google Scholar
• Lu, K. H., 2018. Screening for ovarian cancer in asymptomatic women. JAMA, 319 (6), 557–558.
   PubMed Web of Science ®Google Scholar
• Lycke, M., Kristjansdottir, B. and Sundfeldt, K., 2018. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecologic Oncology, 151 (1), 159–165.
   PubMed Web of Science ®Google Scholar
• Marcato, P., et al., 2011. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle, 10 (9), 1378–1384.
   PubMed Web of Science ®Google Scholar
• McKinnon, B., et al., 2015. Comparison of ovarian cancer markers in endometriosis favours HE4 over CA125. Molecular Medicine Reports, 12 (4), 5179–5184.
   Google Scholar
• Menon, U. and Jacobs, I. J., 2001. Ovarian cancer screening in the general population: current status. International Journal of Gynecologic Cancer, 11(0), 3–6.
   Google Scholar
• Micha, J. P., et al., 2009. Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma. International Journal of Gynecologic Cancer, 19 (2), 239–241.
   PubMed Web of Science ®Google Scholar
• Midulla, C., et al., 2012. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 33 (5), 1291–1298.
   PubMed Web of Science ®Google Scholar
• Mirza, M. R., et al., 2016. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. The New England Journal of Medicine, 375 (22), 2154–2164.
   PubMed Web of Science ®Google Scholar
• Modell, H., et al., 2015. A physiologist’s view of homeostasis. Advances in Physiology Education, 39 (4), 259–266.
   PubMed Web of Science ®Google Scholar
• Mok, S. C., et al., 2001. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. Journal of the National Cancer Institute, 93 (19), 1458–1464.
   PubMed Web of Science ®Google Scholar
• Momenimovahed, Z., et al., 2019. Ovarian cancer in the world: epidemiology and risk factors. International Journal of Women’s Health, 11, 287–299.
   PubMed Web of Science ®Google Scholar
• Moore, R. G., et al., 2008. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology, 108 (2), 402–408.
   PubMed Web of Science ®Google Scholar
• Moore, L. E., et al., 2006. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiology, Biomarkers & Prevention, 15 (9), 1641–1646.
   PubMed Web of Science ®Google Scholar
• Mor, G., et al., 2005. Serum protein markers for early detection of ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 102 (21), 7677–7682.
   PubMed Web of Science ®Google Scholar
• Muinao, T., Boruah, H. P. D. and Pal, M., 2018. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells–An updated review. Experimental Cell Research, 362 (1), 1–10.
   PubMed Web of Science ®Google Scholar
• Munz, M., Baeuerle, P. A. and Gires, O., 2009. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Research, 69 (14), 5627–5629.
   PubMed Web of Science ®Google Scholar
• Narod, S., 2016. Can advanced-stage ovarian cancer be cured? Nature Reviews Clinical Oncology, 13 (4), 255–261.
   PubMed Web of Science ®Google Scholar
• Nguyen, L., et al., 2013. Biomarkers for early detection of ovarian cancer. Women’s Health (London, England), 9 (2), 171–187.
   PubMedGoogle Scholar
• Nolen, B., et al., 2010. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecologic Oncology, 117 (3), 440–445.
   PubMed Web of Science ®Google Scholar
• Norouzi-Barough, L., et al., 2018a. Molecular mechanisms of drug resistance in ovarian cancer. Journal of Cellular Physiology, 233 (6), 4546–4562.
   PubMed Web of Science ®Google Scholar
• Norouzi-Barough, L., et al., 2018b. CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in the human epithelial ovarian cancer cell line. Iranian Journal of Basic Medical Sciences, 21 (2), 181–187.
   PubMed Web of Science ®Google Scholar
• Nosov, V., et al., 2009. Validation of serum biomarkers for detection of early-stage ovarian cancer. American Journal of Obstetrics and Gynecology, 200 (6), 639-e1–639.e5.
   PubMed Web of Science ®Google Scholar
• Nowak, M., et al., 2015. Current clinical application of serum biomarkers to detect ovarian cancer. Przeglad Menopauzalny = Menopause Review, 14 (4), 254–259.
   PubMedGoogle Scholar
• Ozols, R. F., et al., 2004. Focus on epithelial ovarian cancer. Cancer Cell, 5 (1), 19–24.
   PubMed Web of Science ®Google Scholar
• Pal, M. K., Rashid, M. and Bisht, M., 2015. Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, β-2M and ApoA1 using fluorescence spectroscopy with a comparison of surface plasmon resonance (SPR) analysis. Biosensors & Bioelectronics, 73, 146–152.
   PubMed Web of Science ®Google Scholar
• Perkins, G. L., et al., 2003. Serum tumor markers. American Family Physician, 68 (6), 1075–1082.
   PubMed Web of Science ®Google Scholar
• Petricoin, E. F., III, et al., 2002. Use of proteomic patterns in serum to identify ovarian cancer. The Lancet, 359 (9306), 572–577.
   PubMed Web of Science ®Google Scholar
• Plotti, F., et al., 2012. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 33 (6), 2117–2123.
   PubMed Web of Science ®Google Scholar
• Prahm, K. P., et al., 2018. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. PLoS One, 13 (11), e0207319.
   PubMed Web of Science ®Google Scholar
• Raja, F. A., Chopra, N. and Ledermann, J. A., 2012. Optimal first-line treatment in ovarian cancer. Annals of Oncology, 23, x118–x127.
   PubMed Web of Science ®Google Scholar
• Reed, N., et al., 2010. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Annals of Oncology, 21, v31–v36.
   PubMed Web of Science ®Google Scholar
• Rustin, G. J., et al., 2010. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. The Lancet, 376 (9747), 1155–1163.
   PubMed Web of Science ®Google Scholar
• Schummer, M., et al., 1999. Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene, 238 (2), 375–385.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach, H., Hoon, D. S. and Pantel, K., 2011. Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer, 11 (6), 426–437.
   PubMed Web of Science ®Google Scholar
• Sedlaczek, P., et al., 2002. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society, 95 (9), 1886–1893.
   Google Scholar
• Seer, Surveillance, Epidemiology, and End Results Program–Seer. 2016. https://seer.cancer.gov/statfacts/html/ovary.html.
   Google Scholar
• Siegel, R. L., Miller, K. D. and Jemal, A., 2018. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68 (1), 7–30.
   PubMed Web of Science ®Google Scholar
• Simon, R., 2015. Sensitivity, specificity, PPV, and NPV for predictive biomarkers. Journal of the National Cancer Institute, 107 (8), djv153.
   PubMedGoogle Scholar
• Skates, S. J., et al., 2004. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. Journal of Clinical Oncology, 22 (20), 4059–4066.
   PubMed Web of Science ®Google Scholar
• Speeckaert, M. M., Speeckaert, R. and Delanghe, J. R., 2013. Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. Advances in Clinical Chemistry, 59, 1–21.
   PubMed Web of Science ®Google Scholar
• Su, F., et al., 2007. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomarker Insights, 2, 117727190700200.
   Google Scholar
• Sun, Y., Jia, X. and Wu, X., 2016. High expressions of Lgr5 and ALDH1 in primary epithelial ovarian cancer correlate with advanced tumor stage and grade as well as poor prognosis of the patients. Gynecologic and Obstetric Investigation, 81 (2), 162–168.
   Web of Science ®Google Scholar
• Taylor, D. D. and Gercel-Taylor, C., 2008. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic Oncology, 110 (1), 13–21.
   PubMed Web of Science ®Google Scholar
• Terlikowska, K. M., et al., 2016. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. Journal of Ovarian Research, 9 (1), 1–7.
   PubMed Web of Science ®Google Scholar
• Trott, K. R., 1994. Tumour stem cells: the biological concept and its application in cancer treatment. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 30 (1), 1–5.
   PubMed Web of Science ®Google Scholar
• Ueland, F. R., 2017. A perspective on ovarian cancer biomarkers: past, present and yet-to-come. Diagnostics, 7 (1), 14.
   Web of Science ®Google Scholar
• United Nations Environment Programme. International Labour Organization. World Health Organization. International Program on Chemical Safety. 2001. Biomarkers in risk assessment: Validity and validation. Geneva, Switzerland: World Health Organization.
   Google Scholar
• Visintin, I., et al., 2008. Diagnostic markers for early detection of ovarian cancer. Clinical Cancer Research, 14 (4), 1065–1072.
   PubMed Web of Science ®Google Scholar
• Wang, S., et al., 2011. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point of care. Lab Chip, 11 (20), 3411–3418.
   PubMed Web of Science ®Google Scholar
• Webb, P. M. and Jordan, S. J., 2017. Epidemiology of epithelial ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 41, 3–14.
   PubMed Web of Science ®Google Scholar
• Wei, S. U., Li, H. and Zhang, B., 2016. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomedical Reports, 5 (1), 41–44.
   PubMed Web of Science ®Google Scholar
• Weiderpass, E. and Tyczynski, J. E., 2015. Epidemiology of patients with ovarian cancer with and without a BRCA1/2 mutation. Molecular Diagnosis & Therapy, 19 (6), 351–364.
   PubMed Web of Science ®Google Scholar
• Xu, Y., et al., 2016. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: results from 1021 cases in South China. Clinical Biochemistry, 49 (1–2), 32–40.
   PubMed Web of Science ®Google Scholar
• Yang, W. L., Lu, Z. and Bast, R. C., Jr, 2017. The role of biomarkers in the management of epithelial ovarian cancer. Expert Review of Molecular Diagnostics, 17 (6), 577–591.
   PubMed Web of Science ®Google Scholar
• Ye, B., Gagnon, A. and Mok, S. C., 2007. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Review of Proteomics, 4 (1), 121–131.
   PubMed Web of Science ®Google Scholar
• Yokoi, A., et al., 2018. Integrated extracellular microRNA profiling for ovarian cancer screening. Nature Communications, 9 (1), 1–10.
   PubMed Web of Science ®Google Scholar
• Yurkovetsky, Z., et al., 2010. Development of a multimarker assay for early detection of ovarian cancer. Journal of Clinical Oncology, 28 (13), 2159–2166.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., et al., 2004. Three biomarkers were identified from serum proteomic analysis for the detection of early-stage ovarian cancer. Cancer Research, 64 (16), 5882–5890.
   PubMed Web of Science ®Google Scholar
• Zhang, L., Chen, Y. and Wang, K., 2019. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Current Problems in Cancer, 43 (2), 135–144.
   PubMed Web of Science ®Google Scholar
• Zhang, P., et al., 2016. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 37 (2), 2183–2191.
   PubMedGoogle Scholar